Skip to Main Content

Suzanne Ostrand-Rosenberg, Ph.D.

Professor; Robert and Jane Meyerhoff Chair of Biochemistry

Suzanne Rosenberg

Office: BS 221
Phone: 410-455-2237
Lab: BS 204/205
Lab Phone: 410-455-2251

Research Group



Postdoctoral, Johns Hopkins University, 1977
Ph.D., California Institute of Technology, 1975


Thompson JA, Srivastava MK, Bosch JJ, Clements VK, Ksander BR, Ostrand-Rosenberg S.  2008. The absence of invariant chain in MHC II cancer vaccines enhances the activation of tumor-reactive type 1 CD4(+) T lymphocytes.  Cancer Immunol. Immunother. 57:389-398.  E-pub ahead of print.

Bunt SK, Yang L, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S.  2007.  Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression.  Cancer Res. 67:10019-10026.

Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S.  2007. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells.  Cancer Res. 67:4507-4513.

Bunt SK, Hanson EM, Sinha P, Srivastava MK, Clements VK, and Ostrand-Rosenberg S. Tumor associated myeloid-derived suppressor cells. In:  Cancer Immunotherapy: Immune Suppression and Tumor Growth. (Eds:  George Prendergast and Elizabeth Jaffee.  Chapter 17, p. 309.  Elsevier Inc. June 2007.

Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand-Rosenberg S. 2007.  Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response.  J. Immunol. 179:977-983.

Bosch JJ, Thompson JA, Srivastava MK, Iheagwara UK, Murray TG, Lotem M, Ksander BR, Ostrand-Rosenberg S.  2007.   MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells.  Cancer Res. 67:4499-4506.

Dolan BP, Gibbs KD Jr., and Ostrand-Rosenberg, Suzanne.  2006. Dendritic cells cross-dressed with peptide MHC class I complexes prime CD8+ T cells.  J. Immunol. 177:6018-6024

Bunt SK, Sinha P Clements VK, Leips J and Ostrand-Rosenberg S.  2006.  Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression.  J. Immunol. 176:284-290.

Thompson JA, Dissanayake SK, Ksander BR, Knutson KL, Disis ML and Ostrand-Rosenberg S.  2006.  Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain.  Cancer Res. 66:1147-1154.

Dolan BP, Gibbs KD Jr., and Ostrand-Rosenberg, Suzanne.  2006. Tumor-specific CD4+ T cells are activated by “cross-dressed” dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines.  J. Immunol. 176:1447-1455.

Ostrand-Rosenberg, S. and P. Sinha, 2008.  Macrophages and Tumor Development.  In:  Tumor-induced immune suppression (D. Gabrilovich and A. Hurwitz, eds.), Springer, pp. 131-155.

Ostrand-Rosenberg, S., 2008.  Immune surveillance:  a balance between protumor and antitumor immunity.  Curr. Opin. Genetics & Devel. 18:1-8

Ostrand-Rosenberg, S., 2008.  Cancer and complement.  Nature Biotech 26: 1348-1349.
[Abstract] [PDF]

Kundu, N., X. Ma, D. Holt, O. Goloubeva, S. Ostrand-Rosenberg, and A. Fulton, 2008.  Antagonism of the prostaglandin E receptor EP4 inhibits metastasis and enhances NK function.  Breast Cancer Res. Treat. epub ahead of print


Immune Suppression, Inflammation, and Tumor Progression
Medical University of South Carolina
January 8, 2008

Immune Suppression, Inflammation, and Tumor Progression
S. Ostrand-Rosenberg
FDA, Washington, DC
March 7, 2008

Immune surveillance against cancer: a balance between pro- and anti-tumor immunity
Molecular Biology in Clinical Oncology
S. Ostrand-Rosenberg
Aspen, CO (July 11-18, 2008)
July 16, 2009

Uveal melanoma MHC II vaccines activate tumor-specific cytotoxic T cells and block induction of inhibitor costimulatory molecules
International Congress of Eye Research (ICER)
S. Ostrand-Rosenberg, J. Bosch,U. Iheagawara, and M. Srivastava
Beijing, China (Sept. 24-29, 2008)
September 28, 2009

Inflammation-activated myeloid-derived suppressor cells promote tumor progression and metastasis
Chemical and Biological Aspects of Inflammation and Cancer
S. Ostrand-Rosenberg
>ko Olina, Oahu, Hawaii (Oct. 14-17, 2008)
October 17, 2008

Uveal melanoma MHC II vaccines for the treatment of metastatic uveal melanoma
American Association of Ophthalmology and European Society of Ophthalmology Joint Conference
S. Ostrand-Rosenberg, J. Bosch, and U. Iheagawara
Atlanta, GA, Nov. 7-11, 2008
November 11, 2008

Inflammation-drived myeloid-derived suppressor cells: co-opting anti-tumor immunity to promote tumor progression
American Association of Cancer Research: Frontiers in Cancer Prevention
S. Ostrand-Rosenberg
Washington, DC Nov. 16-19, 2008
November 2, 2008

Understanding Cancer
American Association of Cancer Research: Frontiers in Cancer Prevention
S. Ostrand-Rosenberg
Washington, DC Nov. 16-19, 2008
November 18, 2008

Tumor Induced Immune Suppression: The Inflammation Connection
American Association of Cancer Research: Tumor Immunology: New Perspectives
S. Ostrand-Rosenberg
Miami, FL, (Dec. 2-5, 2008)
December 4, 2008